NEW YORK, March 18, 2013 /PRNewswire/ --
Today, Wall Street Source announced new research reports
highlighting Amgen Inc. (NASDAQ: AMGN), Onyx Pharmaceuticals, Inc.
(NASDAQ: ONXX), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN),
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Incyte Corporation
(NASDAQ: INCY). Today's readers may access these reports free of
charge - including full price targets, industry analysis and
analyst ratings - via the links below.
Amgen Inc. Research Report
As one of the most consistently traded stocks among
biotechnology companies, Amgen has been strategically outlining and
delivering its approach to long-term growth and profitability.
Aside from improving shareholder value, Amgen is committed to
discovering, innovating, developing and manufacturing breakthrough
treatments for unheeded illnesses. Amgen is capitalizing on
major advances in drug discovery and biologics manufacturing as it
boosts its product pipeline. The company reported that one of its
key strategies for growth and profitability is international
expansion and commercialization. Amgen is expected to penetrate new
and emerging markets as it expands its access and value to payers
or end-users. The Full Research Report on Amgen Inc. - including
full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/e763_AMGN]
--
Onyx Pharmaceuticals, Inc. Research
Report
With a vision to grow from a company with three therapies and
four indications to an industry leader, Onyx Pharmaceuticals is
gearing up its operations as it aims to reach more patients
globally. The strong growth of Onyx Pharmaceuticals last year was a
solid basis for the company's near-term momentum for
sustainability. Investors are bullish that the company can achieve
its goals as it continues to rake in revenues and royalties amid
its expansion. Onyx Pharmaceuticals is preparing for US
commercialization as it scouts for opportunities in the
international market. The Full Research Report on Onyx
Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge
at:
[http://www.WallStSource.com/r/full_research_report/fcf8_ONXX]
--
Alexion Pharmaceuticals, Inc. Research
Report
Being the second most innovative company in Forbes' annual
ranking, analysts and investors are optimistic about the future of
Alexion Pharmaceuticals as it continues to advance its nine lead
development programs for Soliris and four additional innovative
therapeutics. Alexion Pharmaceuticals continues to see steady
growth for Soliris as it continues the global commercialization of
the drug. The company is keen on expanding its global presence amid
Soliris' approval for patients with paroxysmal nocturnal
hemoglobinuria (PNH) in US, European Union and Japan. Alexion Pharmaceuticals also acquired
the rights for the first potential treatment for hypophosphatasia
(HPP), and is currently advancing the first-in-class targeted
enzyme replacement therapy to Phase II clinical trials. The Full
Research Report on Alexion Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/451f_ALXN]
--
BioMarin Pharmaceutical Inc. Research
Report
With increased efforts for research and development, BioMarin
Pharmaceuticals is growing its business by boosting its commercial
portfolio. BioMarin Pharmaceuticals' product pipeline has helped
the company surpass its $500 million
revenue. The company believes that its portfolio will continue to
propel the company while improving shareholder value. BioMarin
Pharmaceuticals' reported that it expects to receive the first
regulatory approval for Vimizim by the end of this year. The Full
Research Report on BioMarin Pharmaceutical Inc. - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/936c_BMRN]
--
Incyte Corporation Research Report
The quarter-over-quarter growth of Incyte last year highlights
the company's growth potential as it continues to deploy its
financial strategies. Incyte is expecting an increase in research
and development as the company partners with Lilly for the Phase
III study of baricitinib. In a 2013 financial guidance report,
Incyte also highlighted its $66
million milestone payment for Jakafi under the Novartis and
Lilly collaborative agreements. Analysts and investors have high
hopes in the company as it possesses growth potential in the
international market. The Full Research Report on Incyte
Corporation - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.WallStSource.com/r/full_research_report/0762_INCY]
--
Consider Wall Street Source
Tired of hearing about the latest, greatest trade opportunity...
only to realize that the ship has long sailed? You need a strong,
informative community in your arsenal. Join the group that has been
consistently identifying momentous situations as they develop -
long before they become the next top news on major financial
networks.
Contact: Joe Thomas
Email: press@wallstsource.com
Main: +1-310-496-8071 (North
America)
SOURCE Wall Street Source